BCT197 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Disease, Chronic Obstructive
Conditions
Pulmonary Disease, Chronic Obstructive
Trial Timeline
Aug 1, 2016 → Nov 28, 2017
NCT ID
NCT02700919About BCT197 + Placebo
BCT197 + Placebo is a phase 2 stage product being developed by Mereo BioPharma for Pulmonary Disease, Chronic Obstructive. The current trial status is completed. This product is registered under clinical trial identifier NCT02700919. Target conditions include Pulmonary Disease, Chronic Obstructive.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Disease, Chronic Obstructive were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02700919 | Phase 2 | Completed |
Competing Products
20 competing products in Pulmonary Disease, Chronic Obstructive